MR
Therapeutic Areas
Celldex Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Barzolvolimab (CDX-0159) | Chronic Spontaneous Urticaria (CSU) | Phase 2b |
| CDX-1149 | Solid Tumors | Phase 1 |
| CDX-585 | Solid Tumors | Phase 1 |
Leadership Team at Celldex Therapeutics
AS
Anthony S. Marucci
Co-founder, President and Chief Executive Officer
SM
Sam Martin
Chief Financial Officer and Senior Vice President
DC
Diane C. Young, M.D.
Senior Vice President and Chief Medical Officer
RT
Richard T. Kenney, M.D.
Vice President, Clinical Development
BC
Boris C. Pasche, M.D., Ph.D., FACP
Chairman of the Board of Directors
JJ
James J. Egan, Ph.D.
Director
GA
Garry A. Neil, M.D.
Director
MJ
Martha J. Demski
Director
FW
Frederick W. Driscoll
Director
AM
Anne M. Phillips, M.D.
Director